COMPARISON
Octreotide vs Semaglutide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Octreotide is authorised or registered in 10 and Semaglutide in 10 of the 10 registers read. Octreotide: highest phase Phase 4 (after approval). Semaglutide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Octreotide | Semaglutide | |
|---|---|---|
| Registered trials differs | 344 clinicaltrials.gov · 2026-10-03 | 861 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2025-06-30 ema · 2026-10-03 | 2018-02-08 ema · 2026-10-03 |
| EU withdrawn on differs | 2022-12-02 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for semaglutide |
| ATC code differs | H01CB02 ema · 2026-10-03 | A10BJ06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Octreotide | placebo | Semaglutide | placebo |
|---|---|---|---|---|
| Diarrhoea | 46.2% | 31.7% | 11.8% | 4.5% |
| Nausea | 30.8% | 21.2% | 19.5% | 4.5% |
| Decreased appetite | 28.5% | 15.2% | 6.3% | 1.3% |
| Oedema peripheral | 34.9% | 19.6% | - | - |
| Asthenia | 33.3% | 20.9% | - | - |
| Fatigue | 29.8% | 27.7% | - | - |
| Rash | 28.8% | 14.1% | - | - |
| Hypertension | 26.5% | 19.4% | - | - |
| Dyspnoea | 25.9% | 9.1% | - | - |
| Anaemia | 24.3% | 9.1% | - | - |
| COVID-19 | - | - | 17.0% | 17.8% |
| Constipation | - | - | 8.9% | 2.8% |
| Vomiting | - | - | 8.6% | 1.6% |
| Nasopharyngitis | - | - | 7.5% | 6.1% |
| Dyspepsia | - | - | 5.3% | 1.2% |
| Headache | - | - | 4.0% | 2.1% |
| Upper respiratory tract infection | - | - | 2.7% | 1.9% |
Trial register Octreotide: 5 placebo-controlled trials; Semaglutide: 50. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Octreotide side effects · Semaglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Octreotide | Semaglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.